Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial

Anthony B Miller, Claus Wall, Cornelia J Baines, Ping Sun, Teresa To, Steven A Narod, Anthony B Miller, Claus Wall, Cornelia J Baines, Ping Sun, Teresa To, Steven A Narod

Abstract

Objective: To compare breast cancer incidence and mortality up to 25 years in women aged 40-59 who did or did not undergo mammography screening.

Design: Follow-up of randomised screening trial by centre coordinators, the study's central office, and linkage to cancer registries and vital statistics databases.

Setting: 15 screening centres in six Canadian provinces,1980-85 (Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia).

Participants: 89,835 women, aged 40-59, randomly assigned to mammography (five annual mammography screens) or control (no mammography).

Interventions: Women aged 40-49 in the mammography arm and all women aged 50-59 in both arms received annual physical breast examinations. Women aged 40-49 in the control arm received a single examination followed by usual care in the community.

Main outcome measure: Deaths from breast cancer.

Results: During the five year screening period, 666 invasive breast cancers were diagnosed in the mammography arm (n=44,925 participants) and 524 in the controls (n=44,910), and of these, 180 women in the mammography arm and 171 women in the control arm died of breast cancer during the 25 year follow-up period. The overall hazard ratio for death from breast cancer diagnosed during the screening period associated with mammography was 1.05 (95% confidence interval 0.85 to 1.30). The findings for women aged 40-49 and 50-59 were almost identical. During the entire study period, 3250 women in the mammography arm and 3133 in the control arm had a diagnosis of breast cancer, and 500 and 505, respectively, died of breast cancer. Thus the cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm (hazard ratio 0.99, 95% confidence interval 0.88 to 1.12). After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis.

Conclusion: Annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available. Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4793583/bin/mila016406.f1_default.jpg
Fig 1 Process of randomisation and initial screening (screen 1). Breast examination was carried out by nurses unless stated otherwise (+ve indicates abnormality found by examiner, -ve no abnormality found). MA=mammography (+ve indicates abnormality found by radiologist, -ve no abnormality found). Study surgeon could order diagnostic mammography or consult with the study radiologist if necessary before sending recommendations to family doctors. Bracketed interventions indicate protocol at subsequent screens
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4793583/bin/mila016406.f2_default.jpg
Fig 2 All cause mortality, by assignment to mammography or control arms (all participants)
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4793583/bin/mila016406.f3_default.jpg
Fig 3 Breast cancer specific mortality, by assignment to mammography or control arms (all participants)
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4793583/bin/mila016406.f4_default.jpg
Fig 4 Breast cancer specific mortality from cancers diagnosed in screening period, by assignment to mammography or control arms

References

    1. Miller AB. Conundrums in screening for cancer. Mini review. Int J Cancer 2010;126:1039-46.
    1. Moss S. Over-diagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 2005;7:230-4.
    1. Welch HG. Over-diagnosis and mammography screening. BMJ 2009;339:182-3.
    1. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ 1992;147:1459-76.
    1. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992;147:1477-88.
    1. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women age 50-59 years. J Natl Cancer Inst 2000;92:1490-9.
    1. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 2002;137:305-12.
    1. Leger JL, Naimark AP, Beique R, McFarlane DV, Miller S, Miller AB. Report of the “ad hoc” committee on mammography. J Can Assoc Radiol 1974;25:3-21.
    1. Report of the Working Group to review the National Cancer Institute-American Cancer Society Breast Cancer Detection Demonstration Projects. J Natl Cancer Inst 1979;62:641-709.
    1. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971;215:1777-85.
    1. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 1977;39:2772-82.
    1. Tarone RE. The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study. Cancer 1995;75:997-1003.
    1. Mukherjee S. The emperor of all maladies. A biography of cancer. Simon and Shuster, 2010.
    1. Canadian Breast Cancer Screening Database (CBCSD). Operational procedures and input data dictionary. Version 6. Public Health Agency of Canada, 2012.
    1. Roberts RS, Julian JA, Sweezey D, Muir DC, Shannon HS, Mastromatteo E. A study of mortality in workers engaged in the mining, smelting, and refining of nickel. I: methodology and mortality by major cause groups. Toxicol Ind Health 1989;5:957-74.
    1. Baines CJ, Miller AB, Kopans DB, Moskowitz M, Sanders DE, Sickles EA, et al. Canadian National Breast Screening Study: assessment of technical quality by external review. Am J Roentgenol 1990:155:743-7.
    1. Miller AB, Baines CJ, Sickles EA. Canadian National Breast Screening Study. Am J Roentgenol 1990;155:1133-4.
    1. Baines CJ, McFarlane DV, Wall C. Audit procedures in the National Breast Screening Study: mammography interpretation. Can Assoc Radiol J 1986;37:256-60.
    1. Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260:658-63.
    1. Tabar L, Chen H-H T, Duffy SW, Kruesmo UB. Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. Jpn J Clin Oncol 1999;2129:608-16.
    1. Narod SA. On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet 1997;349:1846.
    1. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
    1. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 2006;332:689-92.
    1. Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 2011;12:1118-24.
    1. Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol 2012;19:249-53.
    1. Gøtzsche PC, Jørgensen KJ, Zahl P-H, Mæhlen J. Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control 2012;23:15-21.

Source: PubMed

3
S'abonner